GONO 的 BRICKET 研究：16 名经 ctDNA 筛选的 BRAF V600E mCRC 患者接受 encorafenib + cetuximab 再治疗后，中位 PFS 为 2.9 个月。
- 30 例患者中有 11 例出现耐药性 ctDNA 突变
#ESMO26 #EMSOAmbassadors。这提醒我们，仅凭分子筛选可能还不够。
11 浏览 · 0 赞 · 0 转发 · 0 回复
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEncorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.org- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.org- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org来源：Evelyn Wong · x.com